|Type||Privately held company|
|Products||Software and consulting|
CLC bio is a bioinformatics software company headquartered in Aarhus, Denmark, and with offices in Cambridge, Massachusetts, Tokyo, Taipei and Delhi. CLC bio's software has more than 250,000 users  in more than 100 countries around the globe.
CLC bio develops widely cited desktop and backend server software for analysis of biological data. While offering some open source algorithms with their tools, CLC bio have their own implementations of several popular applications, which have been accelerated using SIMD technology.
Among other features, the software supports read mapping of Sanger and high-throughput sequencing data, De novo assembly of Sanger and high-throughput sequencing data, SNP detection on whole genomes of any size, detection of structural variations on whole genomes of any size, ChIP-seq analysis, RNA-Seq analysis, Small RNA analysis and BLAST.
CLC bio's software allows the user to analyze, visualize, and compare genomic, transcriptomic, and epigenomic data from all major high-throughput sequencing platforms such as Illumina, Life Technologies, Roche 454, Pacific Biosciences, and Complete Genomics. CLC bio's software is platform independent and can be used for Mac OS X, Windows, and Linux.
CLC bio’s analysis platform has been installed at several of the world’s premier research institutions and at more than 2000 different organizations around the globe, including the top 10 pharmaceutical companies in the world.
Early on, the company presented own-developed high-performance computing solutions, focusing on accelerating open source algorithms such as HMMER, Smith-Waterman and ClustalW, using FPGA technology. CLC bio is no longer developing their own hardware-based products, but are partnering with companies like SciEngines and Convey to deliver HPC solutions.
CLC bio started commercial activities on January 1, 2005 headquartered in Denmark. It's a profitable, privately owned company with 100 employees. 30% of the employees have a PhD and another 50% have a MSc.